Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent dosage regimen has shown observable outcomes. Our objective is to assess whether continuous infusion of piperacillin/tazobactam is superior in terms of efficacy, safety and cost to the intermittent regimen to treat suspected or proved infections due to gram negative bacteria. The setting is Critical Care Medicine Department at Cairo University Hospitals. Methods A prospective randomized comparative study.
A total of 56 patients were recruited from ICU- Cairo University Hospitals. All adult critically ill patients admitted to Critical Care Medicine Department with suspected or confirmed bacterial infections on admission or during their ICU stay were assessed for inclusion into the study. All patients were subjected to the following: A. Patient's full history: Age, sex ,medical history ,concurrent diseases, concurrent medications B. Patient evaluation and assessment: The following were evaluated at baseline and periodically thereafter until day of stopping antibiotic, discharge and/or death : 1. Kidney functions (Serum creatinine, blood urea nitrogen) 2. Liver functions (ALT, AST, Bil D, Bil T, Albumin) 3. Complete blood count 4. Microbiological Evaluation: Cultures and sensitivity tests from suspected site of infection 5. Clinical signs and symptoms of infection documented by the attending physician on patient's medical record 6. APACHE II Variables
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
56
Continuous infusion
Intermittent infusion
Cairo University Hospitals
Cairo, Egypt
Clinical cure
Clinical cure, expressed in percentage, will be considered fulfilled if all the following criteria are met : Cure or improvement of clinical signs and symptoms caused by the infection, normalized WBCs and body temperature.
Time frame: ICU length of stay, assessed up to 30 days
Total cost
Cost in Dollars (prices of drugs ,supplies prices, preparation, administration, daily hospital stay cost )
Time frame: ICU length of stay, assessed up to 30 days
ICU Length of stay
ICU Length of stay in Days
Time frame: ICU length of stay, assessed up to 30 days
Mortality
percentage
Time frame: ICU length of stay, assessed up to 30 days
Readmission within 30- days
Days
Time frame: 30 days
Adverse drug events
Any adverse event occurring during study drug administration
Time frame: ICU length of stay, assessed up to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.